• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Medpace Holdings Inc. (Amendment)

    2/8/23 12:57:40 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MEDP alert in real time by email
    SC 13G/A 1 medp223.txt SCHEDULE 13G Amendment No. 3 Name of Issuer: Medpace Holdings, Inc. Title of Class of Securities: Common Stock CUSIP Number: 58506Q109 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 1,637,818 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 1,637,818 Item 8: Shared Dispositive Power: 0 Item 9: Aggregate Amount Owned: 1,637,818 Item 10: Check Box If Aggregate Amount Excludes Certain Shares: N/A Item 11: Percent of Class Owned: 5.3% Item 12: Type of Reporting Person: IA Item 1(a): Name of Issuer: Medpace Holdings, Inc. Item l(b): Address of Issuer: 5375 Medpace Way, Cincinnati, OH 45227 Item 2(a): Name of Person Filing: Wasatch Advisors LP Item 2(b): Address: 505 Wakara Way, Salt Lake City, UT 84108 Item 2(c): Citizenship: Not Applicable Item 2(d): Title of Class of Securities: Common Stock Item 2(e): CUSIP Number: 58506Q109 Item 3(e): Investment Adviser registered under section 203 of the Investment Advisers Act of 1940 Item 4(a): Amount Owned: 1,637,818 Item 4(b): Percent of Class Owned: 5.3% Item 4(c)(i): Sole Voting Power: 1,637,818 Item 4(c)(ii): Shared Voting Power: 0 Item 4(c)(iii): Sole Dispositive Power: 1,637,818 Item 4(c)(iv): Shared Dispositive Power: 0 Item 5: Check Box If Ownership Is 5% or Less of Class: [ ] Item 6. Ownership of More Than 5% on Behalf of Another Person: N/A Item 7: Identification of Subsidiary: Not Applicable Item 8: Identification of Members of Group: Not Applicable Item 9: Notice of Dissolution of Group: Not Applicable Item 10: Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of December 31, 2022. Date: 02/08/23 Signature: /s/JB Taylor Name/Title: JB Taylor/CEO
    Get the next $MEDP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDP

    DatePrice TargetRatingAnalyst
    4/22/2025Outperform → Mkt Perform
    William Blair
    4/14/2025$328.00Buy → Hold
    TD Cowen
    3/24/2025$330.00Market Perform
    Leerink Partners
    10/23/2024$413.00 → $349.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Buy
    Redburn Atlantic
    9/27/2024$420.00 → $350.00Buy → Neutral
    UBS
    9/25/2024$415.00 → $345.00Buy → Hold
    Jefferies
    8/1/2024$415.00Hold
    Truist
    More analyst ratings

    $MEDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Medpace downgraded by William Blair

      William Blair downgraded Medpace from Outperform to Mkt Perform

      4/22/25 10:17:27 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace downgraded by TD Cowen with a new price target

      TD Cowen downgraded Medpace from Buy to Hold and set a new price target of $328.00

      4/14/25 8:14:21 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Leerink Partners initiated coverage on Medpace with a new price target

      Leerink Partners initiated coverage of Medpace with a rating of Market Perform and set a new price target of $330.00

      3/24/25 8:40:00 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Financials

    Live finance-specific insights

    See more
    • Medpace Holdings, Inc. Reports First Quarter 2025 Results

      Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

      4/21/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

      Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

      3/18/25 4:05:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

      Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of

      2/10/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Leadership Updates

    Live Leadership Updates

    See more
    • Medpace Holdings, Inc. Announces Senior Leadership Changes

      Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon

      7/26/21 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    SEC Filings

    See more
    • SEC Form 8-K filed by Medpace Holdings Inc.

      8-K - Medpace Holdings, Inc. (0001668397) (Filer)

      5/16/25 5:11:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 144 filed by Medpace Holdings Inc.

      144 - Medpace Holdings, Inc. (0001668397) (Subject)

      4/24/25 2:13:57 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by Medpace Holdings Inc.

      10-Q - Medpace Holdings, Inc. (0001668397) (Filer)

      4/22/25 4:02:48 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel & Corp. Secy. Ewald Stephen P bought $652 worth of shares (2 units at $326.11), increasing direct ownership by 0.01% to 13,343 units (SEC Form 4)

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      2/28/25 4:39:05 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Zander Dani S.

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:59:16 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Mccarthy Cornelius P. Iii

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:51:25 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Kraft Robert O.

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:45:08 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

      SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

      3/8/24 4:28:58 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

      SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

      2/28/24 5:04:01 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Medpace Holdings Inc. (Amendment)

      SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)

      2/13/24 5:09:38 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medpace Holdings, Inc. Reports First Quarter 2025 Results

      Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

      4/21/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

      Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

      3/18/25 4:05:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

      Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of

      2/10/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care